Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapyMaria Vittoria Dieci, PierFranco Conte, Vassilena Tsvetkova et al.|European Journal of Cancer|2020Cited by 74
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancerDavide Massa, Maria Vittoria Dieci, Claudio Vernieri et al.|JNCI Journal of the National Cancer Institute|2024Cited by 32
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant ChemotherapyGrazia Maria Vernaci, Maria Vittoria Dieci, Edoardo Savarino et al.|The Oncologist|2023Cited by 25
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early <i>ERBB2</i>-Positive Breast CancerMaria Vittoria Dieci, Valentina Guarneri, Giancarlo Bisagni et al.|JAMA Oncology|2025Cited by 17
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Maria Vittoria Dieci, Moira Ragazzi et al.|Clinical Cancer Research|2023Cited by 13